ASCO GU 2018: Visceral Metastases on Abiraterone vs. Placebo: A Post-hoc Analysis of Mode of Radiographic Progression In COU-AA-302

San Francisco, CA (UroToday.com) Dr. Teply and colleagues presented a post-hoc analysis of COU-AA-302 [1] assessing mode of radiographic progression. Abiraterone prolongs survival in patients with prostate cancer due to its potent inhibition of androgen synthesis. Increased rates of visceral metastatic disease at the time of progression on abiraterone compared to baseline demonstrate a poor prognostic feature associated with non-AR dependent prostate cancer.

ASCO GU 2018: Occurrence of pathologic stage T3 disease at radical prostatectomy with ISUP grade group 1 (Gleason 3+3=6) prostate cancer

San Francisco, CA (UroToday.com) In this study, the authors focus on outcomes in men with Gleason grade 1 (Gleason score 3+3=6) prostate cancer at the time of final pathology from radical prostatectomy specimens. With growing interest in how best to classify patients with Gleason Grade 1 disease, with some arguing that its clinical course deems it a benign tumor rather than true malignancy, the authors wanted to assess the clinical outcomes of this unique subset of men in their own institutional series.

ASCO GU 2018: Optimal Timing of Post-prostatectomy Radiotherapy For Prostate Cancer With High-risk Pathologic Features: A Multi-institutional Analysis

San Francisco, CA (UroToday.com) The standard of care for high-risk localized prostate cancer remains radical prostatectomy or radiotherapy + ADT. While ongoing studies are re-assessing the utility of neoadjuvant therapy prior radiotherapy or surgery, the standard of care remains unchanged. However, despite the primary modality of definitive therapy, biochemical recurrence in this high-risk population remains high (~50-70%), often necessitating multimodal therapy.

ASCO GU 2018: Evaluation of a Predefined as Threshold in a Large Cohort of Men with Localized Prostate Cancer

San Francisco, CA (UroToday.com) Recently, a clinical cell−cycle risk (CCR) score has been developed to include both molecular [cell cycle progression (CCP) RNA signature] and clinical [Cancer of the Prostate Risk Assessment (CAPRA)] features.1 Previous validations have demonstrated that this combined CCR score provides improved prognostic information relative to molecular or clinical features alone - in a cohort of men with NCCN-defined low-risk PCa, the CCP score improved clinical risk stratification of men who were at increased risk of BCR.2 As such, a CCR threshold score may help identify men with low−risk disease who may be candidates for active surveillance (AS).

ASCO GU 2018: Impact of 2012 USPSTF Prostate Cancer Screening Recommendations on Prostate Cancer Detection and Presentation at Kaiser Permanente Northern California (KPNC)

San Francisco, CA (UroToday.com) The Kaiser Permanente hospital system, known for its vertical integration in the healthcare system, provides a unique opportunity for clinical research. Similar to a nationalized healthcare system in other countries, as all patient care occurs within the same system, there is the ability for close patient follow-up.

ASCO GU 2018: Prospective Analysis of 4,474 Prostate Biopsies to Evaluate Potential Treatment Management Impact of Combined Clinical-genomic Risk Classification

San Francisco, CA (UroToday.com) There is growing evidence that genomic classification of malignancies, including prostate cancer, may help overcome the heterogeneity and inherent subjective flaws of clinical staging systems. Genomic tests for prostate cancer abound, with many addressing PCa in its various clinical stages. Some are based on prostate biopsy tissue, while others are based on prostatectomy or metastatectomy specimens. Decipher, one of those genomic tests, has been well studied in the literature.

ASCO GU 2018: Life After Prostate Cancer Diagnosis: One Step Beyond

San Francisco, CA (UroToday.com) In the current era of prostate cancer management, we sometimes forget to look at the bigger picture. In this cross-sectional study, the authors evaluate the whole PCa population compared to the general population. While other studies often focus on very specific subsets of PCa patients, this data can help provide a broader, albeit less specific, picture of how PCa patients are doing compared to the general population.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe